Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with Albumin Paclitaxel and Carboplatin for TNBC
NCT03650738Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in triple-negative breast cancer (TNBC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Pathologic Complete Response rate at 4 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03650738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03650738.